Free Trial

Kalaris Therapeutics (KLRS) Competitors

Kalaris Therapeutics logo
$2.76 -0.08 (-2.82%)
As of 04:00 PM Eastern

KLRS vs. BDTX, GALT, IPHA, SLS, ACRS, IMAB, TIL, PBYI, KYTX, and DERM

Should you be buying Kalaris Therapeutics stock or one of its competitors? The main competitors of Kalaris Therapeutics include Black Diamond Therapeutics (BDTX), Galectin Therapeutics (GALT), Innate Pharma (IPHA), SELLAS Life Sciences Group (SLS), Aclaris Therapeutics (ACRS), I-Mab (IMAB), Instil Bio (TIL), Puma Biotechnology (PBYI), Kyverna Therapeutics (KYTX), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

Kalaris Therapeutics vs. Its Competitors

Black Diamond Therapeutics (NASDAQ:BDTX) and Kalaris Therapeutics (NASDAQ:KLRS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Black Diamond Therapeutics presently has a consensus target price of $12.80, suggesting a potential upside of 330.98%. Kalaris Therapeutics has a consensus target price of $3.00, suggesting a potential upside of 8.70%. Given Black Diamond Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Black Diamond Therapeutics is more favorable than Kalaris Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Black Diamond Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00
Kalaris Therapeutics
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Black Diamond Therapeutics' return on equity of 4.70% beat Kalaris Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Black Diamond TherapeuticsN/A 4.70% 3.47%
Kalaris Therapeutics N/A -62.08%-54.69%

95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 66.1% of Kalaris Therapeutics shares are owned by institutional investors. 6.0% of Black Diamond Therapeutics shares are owned by insiders. Comparatively, 75.0% of Kalaris Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Black Diamond Therapeutics has a beta of 2.71, indicating that its share price is 171% more volatile than the S&P 500. Comparatively, Kalaris Therapeutics has a beta of 0.48, indicating that its share price is 52% less volatile than the S&P 500.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Black Diamond TherapeuticsN/AN/A-$69.68M$0.0649.50
Kalaris TherapeuticsN/AN/A-$58.77MN/AN/A

In the previous week, Kalaris Therapeutics had 1 more articles in the media than Black Diamond Therapeutics. MarketBeat recorded 2 mentions for Kalaris Therapeutics and 1 mentions for Black Diamond Therapeutics. Black Diamond Therapeutics' average media sentiment score of 1.91 beat Kalaris Therapeutics' score of 1.44 indicating that Black Diamond Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Black Diamond Therapeutics Very Positive
Kalaris Therapeutics Positive

Summary

Black Diamond Therapeutics beats Kalaris Therapeutics on 8 of the 11 factors compared between the two stocks.

Get Kalaris Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for KLRS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KLRS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

KLRS vs. The Competition

MetricKalaris TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$51.61M$3.04B$5.74B$9.51B
Dividend YieldN/A2.40%4.60%3.99%
P/E RatioN/A21.1828.1120.03
Price / SalesN/A339.43461.37103.88
Price / CashN/A43.2336.5559.01
Price / Book0.128.368.655.90
Net Income-$58.77M-$55.19M$3.25B$258.66M
7 Day Performance15.48%5.89%4.21%2.22%
1 Month Performance6.15%17.63%10.82%12.76%
1 Year PerformanceN/A5.09%34.70%19.36%

Kalaris Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
KLRS
Kalaris Therapeutics
0.8869 of 5 stars
$2.76
-2.8%
$3.00
+8.7%
N/A$51.61MN/A0.00110Analyst Forecast
BDTX
Black Diamond Therapeutics
2.9635 of 5 stars
$3.13
-2.5%
$12.80
+308.9%
-48.7%$177.98MN/A52.1790Positive News
GALT
Galectin Therapeutics
2.4432 of 5 stars
$2.80
-3.1%
$6.00
+114.3%
+14.0%$177.22MN/A-3.899
IPHA
Innate Pharma
2.6261 of 5 stars
$1.92
+8.5%
$11.00
+472.9%
-10.0%$176.98M$12.62M0.00220Gap Up
SLS
SELLAS Life Sciences Group
2.3325 of 5 stars
$1.77
-6.8%
$7.00
+295.5%
+53.8%$176.61MN/A-4.6610Positive News
ACRS
Aclaris Therapeutics
2.3799 of 5 stars
$1.61
+1.3%
$8.71
+441.3%
+21.7%$174.33M$18.72M-1.16100Positive News
Gap Up
IMAB
I-Mab
2.869 of 5 stars
$2.10
-2.8%
$6.00
+185.7%
+50.4%$171.49M$3.89M0.00380
TIL
Instil Bio
3.1676 of 5 stars
$26.10
-5.8%
$119.00
+355.9%
+151.7%$171.19MN/A-2.18410Positive News
PBYI
Puma Biotechnology
4.233 of 5 stars
$3.40
+1.2%
$7.00
+105.9%
-8.8%$168.75M$230.50M4.42200Upcoming Earnings
KYTX
Kyverna Therapeutics
2.7116 of 5 stars
$3.90
-4.2%
$18.50
+374.4%
-52.5%$168.55MN/A-1.1596
DERM
Journey Medical
2.331 of 5 stars
$7.19
-1.5%
$9.50
+32.1%
+42.0%$167.50M$56.13M-18.4490

Related Companies and Tools


This page (NASDAQ:KLRS) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners